Nothing said here yet.
to join the conversation.
| Alan Armstrong | Buy | $8.0K | Mon, Mar 30 | Tue, Jul 21 |
argenx has delivered powerful long term gains, and the latest jump on fresh clinical data has put an even brighter spotlight on whether the current share price is adequately supported by its earnings.
argenx (ENXTBR:ARGX) just released its Q3 2026 results, giving investors a detailed look at how its autoimmune portfolio is translating into revenue, profit and earnings per share.
Argenx (ENXTBR:ARGX) reported positive topline Phase 3 ALKIVIA trial results for VYVGART in autoimmune myositis patients. The study met its primary endpoint, showing clinically meaningful improvement over placebo in both IMNM and dermatomyositis groups.
Argenx came into this Q3 2026 report with a rich biotech valuation and a reputation as a high conviction growth story.
Argenx's (ARGX) Q3 results highlighted continued growth in Vyvgart sales, while its acquisition of F
Argenx's (ARGX) Vyvgart sales beat expectations in Q3, with investors focused on upcoming multifocal
VYVGART revenue surged 54% year-over-year amid strategic Forte Biosciences acquisition.
argenex (NASDAQ:ARGX) reported third-quarter 2026 product net sales of $1.7 billion, up 54% from a year earlier and 13% sequentially, as patient growth in generalized myasthenia gravis, or MG, and chronic inflammatory demyelinating polyneuropathy, or CIDP,…
Argenx stock wavered early Thursday despite beating sales expectations on a surprise testing requirement for its drug, Vyvgart.
HRMY vs. ARGX: Which Stock Is the Better Value Option?
Investing.com -- Argenx shares slipped more than 2% Thursday after the biotech’s third-quarter operating profit came in well below consensus, while sales of its main drug, Vyvgart, beat expectations.